Pacific Biosciences Of California (PACB) Leases (2017 - 2026)

Pacific Biosciences Of California has reported Leases for 9 years, with the latest figure at $40.8 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 8.02% year-over-year to $40.8 million; the trailing twelve-month figure through Mar 2026 stood at $40.8 million (down 8.02% YoY), and the FY2025 full-year result was $41.7 million, up 159.12% from the prior year.
• Leases for Q1 2026 stood at $40.8 million, down from $41.7 million in the prior quarter.
• The five-year high for Leases was $44.9 million in Q1 2022, with the low at $16.1 million in Q4 2024.
• Average Leases over 5 years is $35.9 million, with a median of $39.8 million recorded in 2022.
• Year-over-year, Leases plunged 50.63% in 2024 and jumped 159.12% in 2025.
• Tracing PACB's Leases over 5 years: stood at $39.8 million in 2022, then declined by 18.03% to $32.6 million in 2023, then sank by 50.63% to $16.1 million in 2024, then jumped by 159.12% to $41.7 million in 2025, then slipped by 2.04% to $40.8 million in 2026.
• The last three Leases figures came in at $40.8 million (Q1 2026), $41.7 million (Q4 2025), and $42.6 million (Q3 2025), per Business Quant data.

Peer Comparison